ADDF In The Media

Alzheimer’s Research Forum - A Bird’s-Eye View of Alzheimer’s Research


As research on Alzheimer's disease becomes a growing societal priority worldwide, the National Institute on Aging and the Alzheimer's Association have launched the International Alzheimer's Disease Research Portfolio (IARDP). By organizing thousands of studies on AD into one central database, IADRP will help sponsors identify funded research to avoid duplication, coordinate funding efforts, and spot gaps in support. Researchers may find it useful for the same reasons. With the participation of nine funding agencies and four more that joined recently, the organizers aim to create a comprehensive overview of global efforts to fund Alzheimer's research.

Metabolic Solutions presents Phase 2a clinical trial results at 14th International ADDF Conference


Metabolic Solutions Development Company, LLC (MSDC) has announced that Jerry Colca, PhD, co-founder and chief scientific officer of MSDC, will present results of a Phase 2a study on September 9 at the 14th International Conference on Alzheimer's Drug Discovery. In people with dementia due to Alzheimer's disease (AD) who were not diabetic, the study found that the mTOT(TM)-modulating insulin sensitizer (MSDC-0160) maintained glucose metabolism in key regions of the brain associated with cognitive decline due to AD, as confirmed by FDG-PET imaging.

The Hill: Medicare Proposes a Barrier to an Innovative Alzheimer’s Diagnostic Tool


Earlier this month, the Centers for Medicare and Medicaid Services (CMS) issued a draft Decision Memorandum to deny Medicare reimbursements to patients using an innovative FDA-approved Alzheimer's diagnostic technology designed to help physicians identify whether patients with signs of cognitive impairment may have Alzheimer's or are in fact suffering from another form of dementia. This information is vital to patients, their providers, choices regarding their treatment and their ultimate health outcomes. Academia, Early-Stage Biotech Companies Increasingly Look to CROs to Fill Gap


Academia, Early-Stage Biotech Companies Increasingly Look to CROs to Fill Gaps

Academia and early-stage biotech companies are more frequently looking to fill holes in their expertise and preclinical capacities through the use of CROs, according to a commentary in Nature Reviews Drug Discovery.

MedCity News: Alzheimer’s drug developers get their own version of for CROs


Big pharma’s move to outsource much of its research and development needs to contract research organizations have helped create a thriving CRO industry. The Alzheimer’s Drug Discovery Foundation wants to help academic institutions and small biotechnology companies connect with CROs to make drug development more efficient. It’s launched a social network it compares to so drug developers can more easily find people and companies that can support their preclinical development work.

Genetic Engineering & Biotechnology News: Seeking New Tools Against Alzheimer’s


With just five successes, all just slowing progression of symptoms for six to 12 months, the road to an Alzheimer’s drug has been paved with failure. And the setbacks keep coming, most recently in May, when Baxter International’s Gammagard failed in Phase III to reduce cognitive decline or preserve functional ability in mild-to-moderate Alzheimer’s patients.

Neighborhood Newspapers: Event to raise funds for, awareness of Alzheimer’s disease


Mary Rose Taylor knows first-hand the toll Alzheimer’s disease takes on people and their families.

The Buckhead resident’s husband, Mack, was diagnosed with Alzheimer’s, which causes dementia including memory loss and behavior problems, in 1996 at age 67. He died in 2008 and was a patient of Dr. Allen Levey, director of the Emory University Alzheimer’s Disease Research Center and chairman of the DeKalb County college’s neurology department.

Atlanta Journal Constitution: Luncheon to raise funds for Alzheimer’s research


The Alzheimer’s Society of Atlanta and the Alzheimer’s Drug Discovery Program (ADDF) team up for “Hope on the Horizon” a luncheon, symposium and fundraiser. All of the money raised will go to drug research at Emory’s Alzheimer’s Disease Research Center, led by Dr. Allan Levey. The event also will honor Dan Carithers, an internationally renowned Atlanta-based decorator who has Alzheimer’s.

Washingtonian: Alzheimer’s Research and Jason Wu’s Designs Share the Spotlight at Luncheon


The charitable event was held in a tent that brilliantly defied the spring heatwave outside.

Saks Fifth Avenue and the Alzheimer’s Drug Discovery Foundation can be commended on many fronts, no doubt, but on Thursday they made a remarkable achievement: Under a blazing sun and with temperatures in the 80s they hosted a luncheon for 350 people in a large white tent in a parking lot—and managed to keep it as cool as an otherwise spring day. No doubt when they planned their third annual Great Ladies Luncheon for mid-April they did not expect a heatwave. Everyone inside the very cool tent, including many women in their best suits, dresses, and jewelry and a group of runway models, didn’t have to worry about breaking out in a sweat.

ADDF New York Times Letter To the Editor. Key to Fighting Alzheimer’s Costs: New Drugs


Re “Dementia Study Predicts a Surge in Cost and Cases” (front page, April 4):

The projected costs of dementia care are staggering, but this has been known for decades. It’s time we paid more attention to one of the fastest-growing chronic diseases in our country.

The only way to prevent dementia from bankrupting the system is to invest in drug discovery. There are no treatments to prevent or slow Alzheimer’s, the most common dementia. And it’s unlikely that any one drug will be the silver bullet, so we need to pursue many pathways.